#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

People who developed hepatocellular carcinoma after being cured of HCV had cirrhosis and worse liver function.

More than a third of hepatocellular carcinoma cases among Medicare recipients were due to fatty liver disease.

Cases of the most common type of liver cancer, hepatocellular carcinoma, are on the rise.

Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.

Research has shown that elevated levels of iron in the blood from hereditary hemochromatosis can raise the risk of HCC.

From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.

Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.

Use of cholesterol-lowering medications was also associated with reduced mortality from liver cancer and other causes.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.

But a simple improvement in dietary intake reversed fatty liver disease and staved off cancer.

Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.